BioSpace News Archive

Announces completion of enrollment in the pivotal Phase 3 NEPTUNE trial with OV101 in Angelman syndrome; topline results expected in Q4 2020 Multiple data readouts for soticlestat expected in Q3 2020, including from the randomized Phase 2 ELEKTRA trial in Dravet syndrome and Lennox-Gastaut syndrome, the Phase 2 ARCADE trial in CDKL5 deficiency disorder and Dup15q syndrome and the ENDYMION open-label extension study Receipt of Rare Pediatric Disease Designation by the FDA for OV101 for the

Protocol Amendment allows for increase in TIGRIS sites to 15 while potentially accelerating patient enrolling and offsetting any COVID-19 pandemic-related delays

Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that the first patient has been dosed in an investigator-initiated multi-center clinical trial of Allocetra TM in COVID-19 patients with severe illness and respiratory failures. The clinical trial has been designed to assess Allocetra TM in combination with standard of care therapy in patients with COVID-19 associated lung dysfunction. Safet

Volpara Solutions will spotlight the Volpara®Platform™, a comprehensive suite of artificial intelligence and software tools that improve breast cancer detection, at the Association for Medical Imaging Management (AHRA) 2020 virtual conference on August 11-13.

Fapon Biotech Inc. (Fapon), a global leading IVD raw materials and one-stop solutions company, announces a new COVID-19 donation to meet the urgent demand for development and optimization of reliable quality controls for high-quality antibody tests by donating 100 million Anti-SARS-CoV-2 Fully Human RBD IgM & IgG QC test materials. T

China Biologic Products Holdings, Inc. (NASDAQ: CBPO) (“China Biologic” or the “Company”), a leading fully integrated plasma-based biopharmaceutical company in China , today announced that the Company plans to release its second quarter 2020 financial results on Monday, August 17, 2020 after the market closes. The Company’s management

Urges Stockholders to Sign, Date and Promptly Return the BLUE Proxy Card to Support CytRx’s Highly-Experienced Directors at the September 3rd Annual Meeting

Dragonfly Therapeutics, Inc. (“Dragonfly” or the “Company”), today announced that Bristol Myers Squibb (“BMS”) has licensed its fourth TriNKET™ immunotherapy drug candidate from Dr

Basis for the upgrade include Company’s resilience during the pandemic, solid free cash flow and potential for further deleveraging

Verastem Will Receive $70 Million Up-Front with Total Deal Value Up to $311 Million, Plus Double-Digit Sales Royalties Upon Closing, Verastem’s Current Programs Will Be Funded Until At Least 2024 to Develop VS-6766 and Defactinib in Low-Grade Serous Ovarian Cancer and KRAS Mutant Non-Small Cell Lung Cancer Phase 2 Registration-Directed Trials Expected to Commence by Year End 2020 in Both Low-Grade Serous Ovarian Cancer and KRAS Mutant Non-Smal